ArticleTranslational oncology2026
Multi-omics integration identifies prognostic genes linked to adaptive immunity response and radiosensitivity in cervical cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is central to cervical cancer (CC) treatment, yet radiosensitivity remains a key determinant of prognosis. Although adaptive immune response (AIR) influences tumor progression, its role in modulating CC radiosensitivity and the underlying molecular mechanisms remain largely unexplored. This study aims to elucidate the link between AIR and radiosensitivity, and to identify novel therapeutic targets.
methodsMulti-omics data were integrated to identify AIR-related prognostic genes via differential expression, weighted gene co-expression network analysis (WGCNA), univariate Cox, and least absolute shrinkage and selection operator (LASSO) analyses. A risk model was constructed and validated. Functional enrichment, immune infiltration, and drug sensitivity were assessed. Clinical validation used immunohistochemistry, and a radioresistant cell line was established. The expression levels of the key genes were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting; colony formation assays evaluated radiosensitivity following their knockdown.
resultsTwo genes (ITM2A and TCL1A) were identified to construct a prognostic risk model. High-risk groups exhibited distinct immune pathways, reduced immune infiltration, and altered drug sensitivity. Both genes correlated with mast cell differentiation. Notably, ITM2A and TCL1A were downregulated in radioresistant phenotypes, and their knockdown significantly enhanced post-irradiation colony formation versus controls, indicating a radiosensitizing role.
conclusionsITM2A and TCL1A are identified as novel AIR-related radiosensitivity genes. Our risk model may serve as a potential prognostic stratification tool for CC, offering insights into combinatorial immunotherapy and radiosensitization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.